USV chided by FDA over contamination risks at India site

FDA
Indian drug manufacturer USV was hit with a warning letter from the FDA, which alleged in part that the company lacked proper procedures to prevent contamination risks. (Sarah Silbiger/Stringer/Getty Images News)

Indian drug manufacturer USV was hit with a warning letter from the FDA outlining three violations, which largely centered on a lack of procedures that could lead to microbial and particulate contamination.

The rebuke from the U.S. regulator follows an April 7 to April 17 inspection this year of the company’s facility at India's Mahatma Gandhi Udyognagar industrial estate. 

The inspection found USV lacked required written procedures focused on the prevention of microbial contamination for sterile products, and the company was also dinged for not having separate or defined areas to prevent contamination mix-ups.

“The aseptic processing operations have fundamental flaws in design leading to unidirectional airflow deficiencies, poor ergonomics and deficient aseptic practices,” the FDA said in its letter, dated Nov. 2. 

USV enlisted consultants in an effort to remedy its process design, but according to the FDA, the company lacked "sufficient commitment to comprehensively remediate your aseptic processing operations." This would have required "complete assessment of your aseptic processing operation," plus "equipment replacement," per the agency. 

USV was also cited for failing to develop lab controls to make sure that all elements it's manufacturing conformed to appropriate standards of identity, strength, quality and purity.

The FDA also said USV’s visual inspection program was inadequate in determining if the drug products produced at the site were free of visible particulates.

Moreover, the company "failed to investigate atypical trends" in certain injectable drug batches, the identities of which were redacted in the FDA write-up. 

Going forward, the FDA outlined a list of actions for USV to take, including establishing a CAPA program and striving toward improved visible particulate contamination inspection and quality systems. 

USV previously indicated to the FDA that it would suspend production of certain drugs bound for the U.S. market. As part of its response to the warning letter, the company should notify the FDA if it intends to resume producing drugs for the U.S. from the site, the agency said. 

The same USV facility was the subject of a 2017 FDA warning letter that uncovered a list of issues, including ones focused on the site’s microbiology testing lab and its investigation protocol surrounding out-of-spec results. The agency also found computer access issues after uncovering 25 deleted test results in the audit trails of two pieces of equipment.